Detalhe da pesquisa
1.
TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation.
Immunity
; 56(7): 1631-1648.e10, 2023 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37392737
2.
Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.
Immunity
; 53(4): 824-839.e10, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33053331
3.
Smoldering multiple myeloma: taking the narrow over the wide path?
Blood
; 143(20): 2025-2028, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38427775
4.
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma.
Blood
; 143(20): 2029-2036, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394666
5.
RAS/RAFlandscape in monoclonal plasma cell conditions.
Blood
; 2024 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643494
6.
Potential future direction of measurable residual disease evaluation in multiple myeloma.
Blood
; 142(18): 1509-1517, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37471603
7.
The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM.
Blood
; 141(13): 1574-1583, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35984902
8.
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.
Blood
; 141(6): 620-633, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36223594
9.
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Blood
; 141(14): 1724-1736, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36603186
10.
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Blood
; 141(11): 1308-1315, 2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375118
11.
MRD in multiple myeloma: does CR really matter?
Blood
; 140(23): 2423-2428, 2022 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35560160
12.
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Blood
; 139(8): 1160-1176, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35201323
13.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Blood
; 139(6): 835-844, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289038
14.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Blood
; 139(4): 492-501, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34269818
15.
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.
Blood
; 139(17): 2666-2672, 2022 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35171994
16.
Requirements for operational cure in multiple myeloma.
Blood
; 138(16): 1406-1411, 2021 10 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34324647
17.
Risk factors in multiple myeloma: is it time for a revision?
Blood
; 137(1): 16-19, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024991
18.
IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.
Blood
; 138(20): 1980-1985, 2021 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34792571
19.
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience.
Blood
; 138(25): 2686-2695, 2021 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34479366
20.
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Blood
; 137(9): 1192-1195, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33080624